PFIZER INC Other Current Liabilities
PFIZER INC (PFE) had Other Current Liabilities of $19.71 billion as of 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-04
- 2026-06-28: Other Liabilities, Current $19.71B.
- 2026-03-29: Other Liabilities, Current $20.11B.
- 2025-12-31: Other Liabilities, Current $19.43B; Other Liabilities, Current as first filed $18.65B.
- 2025-09-28: Other Liabilities, Current $19.51B.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-06-28 | $19.71B 10-Q · filed 2026-08-04 | |
| 2026-03-29 | $20.11B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $19.43B 10-Q · filed 2026-08-04 | $18.65B 10-K · filed 2026-02-26 |
| 2025-09-28 | $19.51B 10-Q · filed 2025-11-04 | |
| 2025-06-29 | $18.57B 10-Q · filed 2025-08-05 | |
| 2025-03-30 | $20.02B 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $19.72B 10-K · filed 2026-02-26 | |
| 2024-09-29 | $19.92B 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $16.41B 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $18.79B 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $20.54B 10-K · filed 2025-02-27 | |
| 2023-10-01 | $16.78B 10-Q · filed 2023-11-08 | |
| 2023-07-02 | $16.08B 10-Q · filed 2023-08-09 | |
| 2023-04-02 | $20.25B 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $22.57B 10-K · filed 2024-02-22 | |
| 2022-10-02 | $19.65B 10-Q · filed 2022-11-09 | |
| 2022-07-03 | $23.82B 10-Q · filed 2022-08-10 | |
| 2022-04-03 | $24.58B 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $24.94B 10-K · filed 2023-02-23 | |
| 2021-10-03 | $20.69B 10-Q · filed 2021-11-12 | |
| 2021-07-04 | $17.22B 10-Q · filed 2021-08-12 | |
| 2021-04-04 | $12.80B 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $11.56B 10-K · filed 2022-02-24 | $12.64B 10-K · filed 2021-02-25 |
| 2020-09-27 | $10.68B 10-Q · filed 2020-11-05 | |
| 2020-06-28 | $10.17B 10-Q · filed 2020-08-06 | |
| 2020-03-29 | $10.52B 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $9.33B 10-K · filed 2021-02-25 | $11.08B 10-K · filed 2020-02-27 |
| 2019-09-29 | $10.16B 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $10.11B 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $10.28B 10-Q · filed 2019-05-09 | |
| 2019-01-01 | $11.01B 10-K · filed 2020-02-27 | |
| 2018-12-31 | $10.75B 10-K · filed 2020-02-27 | |
| 2018-09-30 | $10.49B 10-Q · filed 2018-11-08 | |
| 2018-07-01 | $10.13B 10-Q · filed 2018-08-09 | |
| 2018-04-01 | $10.95B 10-Q · filed 2018-05-10 | |
| 2018-01-01 | $10.99B 10-K · filed 2019-02-28 | |
| 2017-12-31 | $11.12B 10-K · filed 2019-02-28 | |
| 2017-10-01 | $10.45B 10-Q · filed 2017-11-09 | |
| 2017-07-02 | $10.15B 10-Q · filed 2017-08-10 | |
| 2017-04-02 | $11.14B 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $11.02B 10-K · filed 2018-02-22 | |
| 2016-10-02 | $12.62B 10-Q · filed 2016-11-10 | |
| 2016-07-03 | $11.05B 10-Q · filed 2016-08-11 | |
| 2016-04-03 | $11.42B 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $10.99B 10-K · filed 2017-02-23 | |
| 2015-09-27 | $9.67B 10-Q · filed 2015-11-05 | |
| 2015-06-28 | $8.39B 10-Q · filed 2015-08-06 | |
| 2015-03-29 | $8.32B 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $9.15B 10-K · filed 2016-02-29 | $9.02B 10-K · filed 2015-02-27 |
| 2014-09-28 | $8.82B 10-Q · filed 2014-11-06 | |
| 2014-06-29 | $9.35B 10-Q · filed 2014-08-07 | |
| 2014-03-30 | $10.31B 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $9.97B 10-K · filed 2015-02-27 | $9.95B 10-K · filed 2014-02-28 |
| 2012-12-31 | $13.81B 10-K · filed 2014-02-28 | |
| 2009-09-27 | $10.58B 10-Q · filed 2009-11-05 | |
| 2009-06-28 | $12.63B 10-Q · filed 2009-08-06 | |
| 2008-12-31 | $11.04B 10-Q · filed 2009-11-05 | $11.46B 10-Q · filed 2009-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |